JP2023533855A5 - - Google Patents

Info

Publication number
JP2023533855A5
JP2023533855A5 JP2023502881A JP2023502881A JP2023533855A5 JP 2023533855 A5 JP2023533855 A5 JP 2023533855A5 JP 2023502881 A JP2023502881 A JP 2023502881A JP 2023502881 A JP2023502881 A JP 2023502881A JP 2023533855 A5 JP2023533855 A5 JP 2023533855A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
formula
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023502881A
Other languages
English (en)
Japanese (ja)
Other versions
JP7867482B2 (ja
JP2023533855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034599 external-priority patent/WO2022015423A1/en
Publication of JP2023533855A publication Critical patent/JP2023533855A/ja
Publication of JP2023533855A5 publication Critical patent/JP2023533855A5/ja
Application granted granted Critical
Publication of JP7867482B2 publication Critical patent/JP7867482B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023502881A 2020-07-16 2021-05-27 イソキノリン化合物およびそのAhR不均衡の治療への使用 Active JP7867482B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063052574P 2020-07-16 2020-07-16
US202063052561P 2020-07-16 2020-07-16
US63/052,574 2020-07-16
US63/052,561 2020-07-16
PCT/US2021/034599 WO2022015423A1 (en) 2020-07-16 2021-05-27 ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Publications (3)

Publication Number Publication Date
JP2023533855A JP2023533855A (ja) 2023-08-04
JP2023533855A5 true JP2023533855A5 (enExample) 2025-09-12
JP7867482B2 JP7867482B2 (ja) 2026-05-29

Family

ID=79293345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502881A Active JP7867482B2 (ja) 2020-07-16 2021-05-27 イソキノリン化合物およびそのAhR不均衡の治療への使用

Country Status (10)

Country Link
US (5) US11267788B2 (enExample)
EP (2) EP4786453A2 (enExample)
JP (1) JP7867482B2 (enExample)
KR (1) KR20230041021A (enExample)
CN (1) CN116157387B (enExample)
AU (1) AU2021308209A1 (enExample)
CA (1) CA3185793A1 (enExample)
IL (1) IL299756A (enExample)
MX (1) MX2023000263A (enExample)
WO (1) WO2022015423A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance
WO2024020170A1 (en) * 2022-07-21 2024-01-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
US20260069585A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2024152993A1 (zh) * 2023-01-17 2024-07-25 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN117447402A (zh) * 2023-10-18 2024-01-26 德明药泰生物技术(深圳)有限公司 芳香烃受体调节剂类化合物及其制备方法和应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置
WO2026096218A1 (en) * 2024-10-18 2026-05-07 Dermavant Sciences GmbH Pharmaceutical compositions for respiratory administration and methods of treating inflammatory diseases of the lungs
WO2026085237A1 (en) * 2024-10-18 2026-04-23 Dermavant Sciences GmbH Process for preparing 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504791A (ja) 1991-04-10 1994-06-02 オクタマー,インコーポレイティド レトロウィルス複製の阻害のための方法
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999018077A1 (en) * 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
DE60233414D1 (de) 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
CN1596240A (zh) 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1704856A4 (en) 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5439127B2 (ja) 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
US8933096B2 (en) 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
JP7138654B2 (ja) 2017-03-29 2022-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 金属錯体
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN111699192B (zh) 2018-02-13 2024-03-08 Udc爱尔兰有限公司 金属络合物
TWI828664B (zh) 2018-03-19 2024-01-11 愛爾蘭商Udc愛爾蘭責任有限公司 金屬錯合物
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799B (zh) * 2023-03-08 2024-05-03 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Similar Documents

Publication Publication Date Title
CN112839927B (zh) 新颖方法
AP1122A (en) Therapeutically active compounds based on based on based on indazole bioisostere replacement of catechol in PDE4 inhibitors.
JP2802547B2 (ja) 抗炎症剤としてのイソキサゾリン化合物
JP6786520B2 (ja) 選択的アンドロゲン受容体分解剤(sard)リガンド及びその使用方法
JP5913400B2 (ja) 核内受容体結合剤
TW199152B (enExample)
JP6907351B2 (ja) 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
JP2024522990A5 (enExample)
JPH09500146A (ja) 抗炎症剤としての3−アリール−2−イソオキサゾリン類
JPWO2008105515A1 (ja) 新規なヒドロキサム酸誘導体
JPH0586391B2 (enExample)
JP2000510865A (ja) Tnfとpde―ivのインヒビターとしてのキノリンカルボキサミド
JP2010503694A (ja) インテグラーゼ阻害剤を調製するためのプロセスおよび中間体
TWI662019B (zh) Fused tricyclic γ-amino acid derivative, preparation method and application thereof in medicine
TW201138786A (en) Therapeutic compounds
JP2024544060A (ja) Apol1のスピロ環式阻害剤およびこれを使用する方法
TW200831510A (en) Compounds
JP2000501411A (ja) ベンゾフランカルボキサミドおよびスルホンアミド
AU2014258419A2 (en) Dicarboxylic acid compound
DE69520279T2 (de) Bibphenylamid-derivate als 5-ht1d-antagonisten
JPH11506772A (ja) 抗ウイルス化合物
JP2015530993A (ja) 抗ウイルス化合物の合成
JP2005529084A (ja) 結晶性パレコキシブナトリウム
JP5826371B2 (ja) ペメトレキセド塩の製造方法
JP2025502842A5 (enExample)